The first approved agent in the Glitazar's class: Saroglitazar

Current Drug Targets

Volumn 15, Issue 2, 2014, Pages 151-155

  Agrawal, Ritesh ^a  

^a GOVERNMENT SCIENCE COLLEGE   (India)

Author keywords

Approval; Cadila; Diabetes; Lipaglyn; NCE; PPAR agonist; Saroglitazar

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FENOFIBRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SAROGLITAZAR; VERY LOW DENSITY LIPOPROTEIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; BODY MASS; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ADULT; CLINICAL TRIALS, PHASE IV AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; LIPID METABOLISM; MIDDLE AGED; PHENYLPROPIONATES; PYRROLES; YOUNG ADULT;

EID: 84892983545     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990199     Document Type: Article

References (19)

1. Yamagishi, S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011; 12(14): 2096-102.
2. Heberlé G, de Azevedo WF Jr. Bio-inspired algorithms applied to molecular docking simulations. Curr Med Chem 2011; 18(9): 1339-52.
3. de Azevedo WF Jr. Structure-based virtual screening. Curr Drug Targets 2010; 11(3): 261-3.
4. Ramesha BT, Gertsch J, Ravikanth G, Priti V, Ganeshaiah KN, Uma Shaanker R. Biodiversity and chemodiversity: future perspectives in bioprospecting. Curr Drug Targets 2011; 12(11): 1515-30.
5. Eberhardt L, Kumar K, Waldmann H. Exploring and exploiting biologically relevant chemical space. Curr Drug Targets 2011; 12(11): 1531-46.
6. Boucher BJ. Vitamin D insufficiency and diabetes risks. Curr Drug Targets 2011; 12(1): 61-87.
7. de Azevedo WF Jr. MolDock applied to structure-based virtual screening. Current Drug Targets 2010: 11(3): 327-4.
8. Dias RF, de Azevedo WF Jr. Molecular docking algorithms. Current Drug Targets 2008; 9(12): 1040-7.
9. de Azevedo WF Jr, Dias R. Computational methods for calculation of ligand-binding affinity. Current Drug Targets 2008; 9(12): 1031-9.
10. Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A, Koya D. Sirtuins as possible drug targets in type IIdiabetes. Curr Drug Targets 2013; 14(6): 622-36.
11. Mooradian AD. Dyslipidemia in type IIDiabetes Mellitus. (1745-8374 (Electronic).
12. Agrawal R, Jain P, Dikshit SN. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (gamma) agonist. Mini Rev Med Chem 2012; 12(2): 87-97.
13. "Zydus Group launches new diabetic drug". http://timesofindia. indiatimes. com/business/india-business/Zydus-Group-launchesnew-diabetic-drug/articleshow/20459662. cms (Accessed Jun 6, 2013). 2013 Jun 6, 2013. 2013.
14. Saroglitazar-First Nce Discovered And Developed In India To Reach The Market Http://Www. Differding. Com/Data/SaroglitazarFirstNceDiscoveredAndDevelopedInIndia. Pdf (Accessed June 07, 2013). 2013.
15. European Patent Office. http://ep. espacenet. com (Accessed June 07, 2013).
16. United States Patent and Trademark Office. http://www. uspto. gov/(Accessed June 01, 2013).
17. LOHRAY B, LOHRAY V, BAROT V, RAVAL S, RAVAL P, BASU S. Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine. WO 200303009841, Feb 6, 2003.
18. Lipaglyn http://lipaglyn. com/doctor. html (Accessed June 27, 2013). 2013.
19. Saroglitazar CTRI/2013/06/003754. http://ctri. nic. in/Clinicaltrials/showallp. php?mid1=6705&EncHid=&userName=Saroglitazar (Accessed June 27, 2013). 2013.